Form 4: Adverum Biotechnologies CFO Linda Rubinstein Acquires Stock Options

Linda Rubinstein, CFO of Adverum Biotechnologies, acquired stock options for 62,083 shares of common stock on August 2, 2024.

Summary

• Linda Rubinstein, the Chief Financial Officer of Adverum Biotechnologies, acquired stock options on August 2, 2024.
• The options grant the right to buy 62,083 shares of Adverum's common stock at an exercise price of $7.15 per share.
• The options vest over three years, with one-third vesting on the first anniversary of August 2, 2024, and the remainder vesting monthly thereafter.
• The options expire on August 1, 2034.
• Following the transaction, Ms. Rubinstein directly owns options for 62,083 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects an executive's increased stake in the company.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• The vesting schedule of one-third on the first anniversary and the remainder monthly thereafter is a typical vesting structure.
• Comparing the size of the grant to those of CFOs at similarly sized biotech companies would provide further context.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates